

1 **Anti-SARS-CoV-2 antibodies seroprevalence among patients submitted to**
2 **treatment for tuberculosis in Rio de Janeiro, Brazil: a cross-sectional study.**

3

4 **Author(s):** Karen Machado Gomes^{a*}, Suzanne Pereira Leite^a, Maria Helena Vieira
5 Moutinho^a, Thatiana Alfena de Souza^a, Rita de Cássia Batista^a, Luiz Claudio Motta de
6 Oliveira^a, Paulo Redner^a, Jesus Pais Ramos^a, Fatima Maria Gomes da Rocha^b, Gisele
7 Pinto de Oliveira^b, Antônio Teva^c, Fernando do Couto Motta^d, Marilda Agudo Mendonça
8 Teixeira de Siqueira^d, Rafael Silva Duarte^e, Francisco Inácio Pinkusfeld Monteiro
9 Bastos^f, Paulo Victor de Sousa Viana^a

10

11 ^a Centro de Referência Professor Helio Fraga, Escola Nacional de Saúde Pública Sergio
12 Arouca, Fundação Oswaldo Cruz – Campus Jacarepaguá, Estrada de Curicica, 2000 -
13 Curicica, Rio de Janeiro - RJ, 22780-195, Brazil.

14 ^b Vice-Diretoria de Ambulatório e Laboratório, Escola Nacional de Saúde Pública Sergio
15 Arouca, Fundação Oswaldo Cruz, Av. Brasil, 4365 - Manguinhos, Rio de Janeiro - RJ,
16 21040-900, Brazil.

17 ^c Departamento de Ciências Biológicas, Escola Nacional de Saúde Pública Sergio
18 Arouca, Fundação Oswaldo Cruz, Av. Brasil, 4365 - Manguinhos, Rio de Janeiro - RJ,
19 21040-900, Brazil.

20 ^d Laboratório de Vírus Respiratórios e Sarampo, Instituto Oswaldo Cruz, Fundação
21 Oswaldo Cruz, Av. Brasil, 4365 - Manguinhos, Rio de Janeiro - RJ, 21040-900, Brazil.

22 ^e Laboratório de Micobactérias, Instituto de Microbiologia Paulo de Góes, Universidade
23 Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373 - bloco I - Cidade Universitária,
24 Rio de Janeiro - RJ, 21941-970, Brazil.

25 ^f Laboratório de Informação em Saúde, Instituto de Comunicação e Informação Científica
26 e Tecnológica em Saúde, Fundação Oswaldo Cruz, Av. Brasil, 4365 – Manguinhos, Rio
27 de Janeiro – RJ, 21040-900, Brazil.

28 * Corresponding author: karen.gomes@ensp.fiocruz.br

29

30 **ABSTRACT**

31 Due to tuberculosis (TB) patients' pulmonary damages, some authors believe that a
32 SARS-CoV-2 coinfection may result in unfavorable outcomes. A cross-sectional anti-
33 SARS-CoV-2 antibodies seroprevalence study was conducted at a TB treatment tertiary
34 referral unit in Rio de Janeiro, Brazil, to estimate the proportion (in %) of TB patients
35 exposed to the new coronavirus and their main outcomes. Of 83 patients undergoing TB
36 treatment, 26.5% have already been infected by the new coronavirus. Most patients were

37 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
asymptomatic (69%) or had mild COVID-19 cases (31%). Only one patient required

38 hospitalization. Among the symptoms and signs presented, the most frequently reported
39 were: fever, headache, and myalgia. People with less education and less purchasing
40 power seemed to had been more exposed to SARS-CoV-2.

41

42 **Keywords:** COVID-19; Tuberculosis; SARS-CoV-2; Coinfection.

43

44 1. Introduction

45 COVID-19 (Coronavirus Disease 2019), caused by the new Betacoronavirus
46 SARS-CoV-2, was first described in Wuhan, China, in December 2019, as responsible
47 for severe pneumonia [1], [2], among several other systemic and organ specific
48 manifestations [3]. Despite the measures taken to curb the epidemic, SARS-CoV-2 has
49 spread throughout the world and has caused thousands of deaths. Until July 30, 2021,
50 196.794.025 cases and 4.202.385 deaths by COVID-19 had been confirmed worldwide.
51 As of the same date, Brazil had 19.839.369 confirmed cases and 554.497 deaths [4]. In
52 contrast to the newest infectious disease to be defined as a pandemic, tuberculosis (TB)
53 is an ancient disease caused by *Mycobacterium tuberculosis* [5]. TB mainly affects the
54 lungs and, until the COVID-19 emergence, it was the leading death caused by a single
55 infectious agent in the world, with estimates, in 2018, of approximately 10 million cases
56 and 1.5 million deaths [6].

57 Due to TB patients' pulmonary functional impairment and unfavorable outcomes
58 in consequence of putative associations with fungal, viral and bacterial pulmonary
59 infections [7]–[11], it has been suggested that TB and COVID-19 coinfection could result
60 in more severe conditions and higher mortality rates [12]. Despite many published
61 studies on COVID-19 in recent months, few have analyzed how this new disease may
62 affect TB patients.

63 Seroprevalence studies are essential because, in addition to estimating the
64 proportion of the population previously infected, helping to assess the time required to
65 reach herd immunity, it may also help to better understand disease transmission patterns
66 [13]. Therefore, to plan an adequate public health response to tuberculosis patients in
67 pandemic times, ideally discerning and anticipating the present and future disease
68 dynamic, the anti-SARS-CoV-2 antibodies level may be crucial. Although some antibody
69 seroprevalence studies for SARS-CoV-2 have been published [13]–[18], none have
70 focused on TB patients (to the best of our knowledge). Thus, we aimed to estimate the
71 seroprevalence of SARS-CoV-2 antibodies in patients undergoing TB treatment and
72 investigate the demographic and clinical characteristics of this population exposed to the
73 new coronavirus.

74

75 **2. Methods**

76

77 **2.1 Study design**

78 A cross-sectional anti-SARS-CoV-2 antibodies seroprevalence study was carried
79 out among a convenience sample of TB and drug-resistant TB (DR-TB) patients assisted
80 at a tertiary referral unit in Rio de Janeiro, Brazil. Participants were screened between
81 September 01, 2020 up to February 28, 2021.

82

83 **2.2 Study Subjects**

84 The *Centro de Referência Professor Hélio Fraga* (CRPHF) is a tertiary reference
85 health unit for TB located in Rio de Janeiro city, Rio de Janeiro, Brazil. Rio de Janeiro is
86 the capital of the homonymous Brazilian state, which has reported the highest new case
87 numbers of TB in 2019 (93.7 cases per 100,000 inhabitants) [6]. Rio de Janeiro was also
88 one of the Brazilian cities with the highest COVID-19 number in 2020, counting 215,016
89 confirmed [19].

90 The CRPHF outpatient clinic treats patients with DR-TB, including multidrug-
91 resistant TB (MDR-TB), extensively drug-resistant TB (XDR-TB), and TB special cases
92 (patients with susceptible-TB who need different treatments due to basic regimen
93 adverse effects). The present study included patients under medical care at the CRPHF
94 undergoing treatment for TB or TB-DR, aged 18 years old or more.

95

96 **2.3 Data collection**

97 Participants answered short standard questionnaires, including socio-
98 demographic information, symptoms related to COVID-19, and access to COVID-19
99 diagnostic tests. Medical records were accessed to investigate clinical and therapeutic
100 TB information.

101

102 **2.4 SARS-CoV-2 serological test**

103 Antibodies prevalence was assessed by the rapid test TR DPP® COVID-19
104 IgM/IgG (Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil), using one drop of blood from
105 a finger prick sample. It is an immunochromatographic test on a differentiated double-
106 path platform for the qualitative detection of IgM and IgG antibodies anti-SARS-CoV-2
107 virus. An electronic device (Micro Reader DPP®) was used to assist in the interpretation
108 of results, reactive or non-reactive.

109 The TR DPP® COVID-19 IgM/IgG (Bio-Manguinhos) was licensed by the Brazilian
110 Health Surveillance Agency (ANVISA) in April 2020 [20]. According to the manufacture
111 specifications its sensitivity was estimated as 79% (95%CI:70.9-86.8%) for IgM and 95%

112 (95%CI:88.8-97.9%) for IgG. The specificity for IgM was estimated as 98.0%
113 (95%CI:95.8-99%) and 97% (95%CI:94-98%) for IgG.

114

115 **2.5 SARS-CoV-2 Real time RT-PCR (RT-qPCR)**

116 The SARS-CoV-2 RT-qPCR was performed for all patients. Naso and
117 oropharyngeal secretions were collected and subjected to total RNA extraction using
118 QIAmp Viral RNA Mini kit (Qiagen, Hilden, Germany). SARS-CoV-2 detection was
119 carried out by SARS-CoV-2 RT-qPCR using the SARS-CoV-2 Molecular E/RP kit
120 (Biomanguinhos, Rio de Janeiro, Brazil) based on the protocol previously designed by
121 Corman et al. [21]. The analyzes were performed at the Respiratory and Measles Viruses
122 Laboratory of the Oswaldo Cruz Institute (IOC/Fiocruz - SARS-CoV-2 National
123 Reference Laboratory for the Brazilian Ministry of Health).

124

125 **2.6 Data analyses**

126 The enrolled patients were characterized using descriptive statistics, stratified by
127 anti-SARS-CoV-2 antibody results. Groups were compared using Fisher's exact test for
128 categorical variables. Anti-SARS-CoV-2 antibodies prevalence and 95% CIs were
129 calculated as the number of positive test results divided by the total number of
130 participants.

131 Data were collected in electronic forms organized on *FormSus* version 3.0
132 (DATASUS), and all analyses were performed using R version 4.1.1 and R Studio
133 version 1.2.1335 software (R Foundation for Statistical Computing).

134

135 **2.7 Ethical considerations**

136 This study was reviewed and approved by the research ethics committee of the
137 Sergio Arouca National School of Public Health / Oswaldo Cruz Foundation (CAAE:
138 32219620.9.0000.5240). Written informed consent was obtained from all study
139 participants.

140

141 **3. Results**

142 A total of 83 participants were interviewed and tested for SARS-CoV-2. Overall
143 study participants were male (60%), 30-59 age group (65%), brown (46%) and 72% with
144 eight or more years of schooling. 39% of participants lived in impoverished communities
145 and 58% declared have a monthly income between one and three minimum wages
146 (Brazilian minimum wages - R\$ 1,100, about \$219 [at the time of their assessment]).
147 Only 14% of participants reported having been previously tested by RT-qPCR for
148 COVID-19 diagnosis, while 25% reported having undergone rapid serological testing.

149 Furthermore, 4.8% stated having had COVID-19 previously. About TB, most participants
150 had pulmonary TB (88%), 70% were new cases and 73% were DR-TB, of which 33%
151 were MDR-TB. The baseline population study characteristics are depicted in **Table 1**.

152 A total of 22 (26.5%; 95%CI:17.0–36.0%) individuals were seropositive for anti-
153 SARS-CoV-2 antibodies. The prevalence by demographics and clinical characteristics is
154 shown in **Table 1**, highlighting: 28.6% (CI95%:4.9-52.2) for people between 19 to 29
155 years old, 30.4% (CI95%:13.1-53.5) for people with less than eight years of schooling,
156 25.0% (CI95%:10.0-40.0) people living in slums, and 27.1% (CI95%:14.5-39.6) patients
157 that receive monthly income between one and three salaries. SARS-CoV-2 antibodies
158 seropositive results were only observed in patients with pulmonary TB (seroprevalence
159 30.1%; CI95%:20.0-42.0). For individuals with DR-TB, the point seroprevalence was
160 29.5% (95%CI:18.0-40.9) whereas for susceptible TB was 18.2% (CI95%:2.0-34.3).

161 By RT-PCR, SARS-CoV-2 was detected in three patients (**Table 2**: patients 2, 7
162 and 18). Patients 2 and 18 non-reagents in the serological test, while patient 7
163 seropositive. Four patients reported having been previously COVID-19 diagnosed (**Table**
164 **2**: patients 2, 5, 22 and 23). Patients 2 and 5, the diagnostic test has been performed
165 approximately 30 days before the interview. Patient 2 presented positive RT-PCR and a
166 negative serological test. Patient 5 presented only a positive serological test. Patients 22
167 and 23, the diagnostic test has been performed nine months before the enrollment in the
168 study and both presented negative results of either RT-PCR and serological test.

169 Adding to patients with a positive serology for SARS-CoV-2, those who detection
170 by RT-PCR and had been previously diagnosed with COVID-19, there were 26 positive
171 patients, 69% (18/26) of them asymptomatic. Among the 31% (8/26) who had had
172 symptoms, 50% reported having up to 4 signs and the other half declared to have had
173 from five to ten. The most common symptoms reported were fever, headache, and
174 myalgias, each one with 75% of reports (multiple answers allowed) (**Table 3**).

175 Among all patients included, 53% (44/83) reported belonging to some priori defined
176 risk group for COVID-19, the most frequently reported were: to be aged over 60 years
177 old (32%) and diabetes (27%). Among patients have been infected by SARS-CoV-2,
178 42% (11/26) presented characteristics associated with a poor prognosis, and the most
179 frequently reported were to be aged over 60 years (15%) and diabetes mellitus (12%)
180 (**Table 4**).

181 Only one patient needed hospitalization because of COVID-19. This patient was
182 previously COVID-19 diagnosed, and in the present study presented negative results for
183 both RT-PCR and serology tests. This patient was diagnosed with TB after has
184 presented COVID-19 symptoms (**Table 2**). This case was the most severe reported in
185 the context of the present study.

186

187 **4. Discussion**

188 This is the first Brazilian anti-SARS-CoV-2 antibodies seroprevalence study in TB
189 patients. The comprehensive assessment of seroprevalence is key because it provides
190 information about the extent of transmission in the past and may help to predict the future
191 course of the pandemic [13], [14]. When this kind of study targets a specific segment of
192 the population, we may infer how these people have been affected. In the present case,
193 the research focus was patients under TB and DR-TB treatment. In addition to COVID-
194 19 tests, a questionnaire was also answered by the patients to assess putative
195 associations and to better understand how these patients have been affected by the
196 COVID-19 pandemic.

197 Our results showed that 26.5% of patients undergoing TB treatment had been
198 infected with the new coronavirus. However, the seroprevalence of anti-SARS-CoV-2
199 antibodies in the present study was higher than previously reported for the city of Rio de
200 Janeiro until now, 7.5% (95%CI:4.5–11.7). This result was reported in a study carried
201 out between April and June 2020 and refers to the general population of Rio de Janeiro
202 [15]. The authors also observed an increase of more than three times between surveys
203 performed 2 to 3 weeks apart (2.4% vs 7.5%). Between June 2020 (last month evaluated
204 by Hallal et al. [15]) and February 2021 (last month when patients were enrolled in the
205 present study), the COVID-19 confirmed cases in the city increased from 56,936 to
206 188,833 cases [22]. Therefore, the seroprevalence differential proportion observed when
207 this study is cross-compared with previous papers may be reflecting the increment in the
208 number of cases that occurred during this period. Furthermore, the fact these different
209 studies have been nested in totally different sampling strategies may help to better
210 understand such marked discrepancies [23]. Several other factors may explain the
211 observed differences, such as different timing, the different tests used in the studies, as
212 well as intrinsic differences between patients recruited in communities compared to those
213 attending health services.

214 Only one former anti-SARS-CoV-2 seroprevalence study assessed TB cases.
215 This research was carried out in Cape Town, South Africa, from August to September
216 2020. They showed that 26.7% of the subjects who reported previous TB had positive
217 serology for SARS-CoV-2, while for the general population it was 23.7% [18]. Gao et al.
218 [24], in a meta-analysis of six studies conducted in China, identified a prevalence of TB
219 among patients with COVID-19 ranging from 0.47 to 4.47%. These authors found that a
220 higher TB prevalence was identified among patients with severe COVID-19 than among
221 non-severe cases (1.47%, 10/680 vs 0.59%, 10/1703; OR: 2.1; p-value=0.24). We must

222 keep in mind that this meta-analysis refers to a set of “reverse” studies, i.e. studies
223 assessing TB among patients with COVID-19, instead of assessing SARS-CoV-2 among
224 patients under management and care for TB.

225 In addition to the small number of publications focused on TB and SARS-CoV-2
226 coinfection, published studies have presented controversial data. While some point to
227 more severe outcomes and even a higher mortality rate among TB patients infected with
228 the new coronavirus [24]–[26], others found a weak or no association between disease
229 severity and/or death in TB patients diagnosed with COVID-19 [27]–[29].

230 In the present study, most patients had mild COVID-19 cases. Among patients
231 with positive serology or a COVID-19 confirmed diagnosis, 69% were asymptomatic, a
232 percentage higher than the ~30% estimated by previous studies [30]–[34]. Among
233 symptomatic patients, fever, headache and myalgia were the most frequently signs
234 reported, differing somewhat from the most common symptoms reported in other studies
235 (fever, dry cough, and dyspnea) [25], [29], [35]. This difference may be related to the fact
236 our patients presented milder COVID-19 cases vis-à-vis those from the abovementioned
237 studies.

238 Although most people develop specific antibodies against SARS-CoV-2 after
239 infection, patients with milder COVID-19 symptoms seem to produce smaller amount of
240 antibodies [36]. In addition, some works have showed a decline of anti-SARS-CoV-2
241 antibody titers over time [36]–[38]. This information may help to explain the seronegative
242 results of two patients who have been COVID-19 diagnosed nine months before the
243 interview. Furthermore, the detection limit of the test and the time required to
244 seroconversion (that may varies among patients [38]), may also interfere with anti-SARS-
245 CoV-2 antibodies detection. These are possible reasons for what might have happened
246 to the patient who had been COVID-19 diagnosed one month before the interview and
247 had no detected antibodies. Due to all abovementioned reasons, we cannot exclude a
248 previous infection in patients with negative serology for SARS-CoV-2.

249 It was impossible to infer any important correlation between the Ct value and
250 serologic response among the patients tested, since only three subjects presented RT-
251 PCR positive results. However, it is worthy to note that the patient which presented
252 antibodies against the virus was the one with the highest Ct value (Ct= 34,9). Such result
253 reinforces the well-known disconnection between virus load and humoral immune
254 response of the patient during respiratory viral infections as observed in other diseases
255 like influenza and syncytial respiratory virus infections.

256 In our study, only one patient required hospitalization, a patient diagnosed with
257 extrapulmonary TB 8 months after the COVID-19 symptoms. TB diagnosis after SARS-
258 CoV-2 infection has been reported by Tadolini et al. [35]. More extensive studies are

259 needed to understand any role of SARS-CoV-2 in the progression of TB infection to
260 disease.

261 Although our small sample size did not allow us to observe significant differences
262 among the socio-demographic categories (putative beta error), some findings should be
263 highlighted. While 72% of respondents reported having more than 8 years of schooling,
264 people with less education seem to be more exposed to SARS CoV-2, as well as those
265 with less purchasing power. This data agrees with results by Horta et al. [16], who
266 analyzed socioeconomic and ethnic status in a seroprevalence study that gathered
267 samples from different Brazilian states.

268 The high DR-TB rate found in our study seems to be associated to the fact that
269 the approach took place in a tertiary health unit, where patients with DR-TB have been
270 mainly referred to management and care. Some authors have questioned whether DR-
271 TB cases would be an additional risk factor for COVID-19 [28]. In the present study, most
272 73% (61/83) coinfecting patients had TB with some resistance, and, in addition, more
273 than half of coinfecting patients have undergone at least one previous TB treatment. Even
274 with these potential aggravating factors, they were asymptomatic or had mild cases of
275 COVID-19.

276 An important measure to curb the COVID-19 spread is mass testing.
277 Unfortunately, this vital strategy to control the pandemic seems has not been carried out
278 in Rio de Janeiro. In our study, 84% of respondents did not have access to RT-PCR tests
279 and 72% to serological tests.

280 This study has some limitations. First, the possible selection bias, since the
281 sample in this study included those who naturally tend to be more mobile and less likely
282 to keep social distancing, first of all to attend their appointments at health facilities, but
283 also to address their bare necessities since most of them are poor and live in
284 impoverished and underserved communities. Second, the small sample size,
285 notwithstanding corresponding to the caseload of a tertiary, referral, health service, are
286 likely affected by type II errors. Furthermore, questionnaires, especially when applied to
287 studies dealing with long-term patients, living with severe diseases, tend to be affected
288 by both recall [39] and social desirability bias [40].

289

290 **5. Conclusions**

291 The present study sought to estimate the prevalence of COVID-19 in patients
292 with TB treatment in Rio de Janeiro, Brazil, considering the fact that this vulnerable
293 population is likely to be severely affected by the epidemic. The 26.5% rate of anti-SARS-

294 CoV-2 antibodies in a population with severe lung problems is of concern, although the
295 risk of serious complications and death remains controversial.

296 Knowing the anti-SARS-CoV-2 antibodies prevalence among patients is
297 essential to better understand COVID-19 spread and help policymakers to implement
298 evidence-based policies to curb the epidemic and to provide coinfecting patients proper
299 management and care. Our data suggest that the high seroprevalence observed among
300 TB patients may be closely associated to the low socioeconomic level of these patients,
301 besides their pressing need to attend successive appointments to manage and care their
302 underlying and putative new medical conditions. To fully adopt social distancing
303 measures in this context, despite being essential, remains a major challenge. In addition
304 to the systematic use of personal protective equipment, these patients should be
305 prioritized by vaccination efforts.

306

307 **Acknowledgements:** To all team members at the Germano Gerhardt Research
308 Outpatient Clinic of the Centro de Referência Professor Hélio Fraga for their support
309 during the development of this project. Bio-Manguinhos (Fiocruz) for the rapid test kits
310 TR DPP® COVID-19 IgM/IgG donation. To the Respiratory Virus and Measles
311 Laboratory (IOC/Fiocruz) for carrying out the SARS-CoV-2 qRT-PCR tests.

312

313 **Funding:** This research did not receive any specific grant from funding agencies in the
314 public, commercial, or not-for-profit sectors.

315

316 **CRedit author statement**

317 **Karen Machado Gomes:** Conceptualization, Methodology, Investigation, Data Curation,
318 Writing - Original Draft, Review & Editing, Visualization, Supervision. **Suzanne Pereira**
319 **Leite:** Methodology, Investigation; Resources; Supervision. **Maria Helena Vieira**
320 **Moutinho:** Investigation. **Thatiana Alfena de Souza:** Investigation. **Rita de Cássia**
321 **Batista:** Investigation. **Luiz Claudio Motta de Oliveira:** Investigation. **Paulo Redner:**
322 Investigation. Writing - Review. **Jesus Pais Ramos:** Writing - Review. **Fatima Maria**
323 **Gomes da Rocha:** Resources. **Gisele Pinto de Oliveira:** Resources. **Antônio Teva:**
324 Resources, Writing - Review. **Fernando do Couto Motta:** Investigation. **Marilda Agudo**
325 **Mendonça Teixeira de Siqueira:** Resources. **Rafael Silva Duarte:** Writing - Review.
326 **Francisco Inácio Pinkusfeld Monteiro Bastos:** Writing – Review. **Paulo Victor de**
327 **Sousa Viana:** Methodology, Formal analysis, Investigation, Resources, Data Curation,
328 Writing Original Draft, Review & Editing.

329

330 **Declaration of interest:** None

331 References

- 332 [1] F. Wu *et al.*, “A new coronavirus associated with human respiratory disease in
333 China,” *Nature*, vol. 579, no. 7798, pp. 265–269, 2020.
- 334 [2] P. Zhou *et al.*, “A pneumonia outbreak associated with a new coronavirus of
335 probable bat origin,” *Nature*, vol. 579, no. 7798, pp. 270–273, 2020.
- 336 [3] M. Ramos-Casals, P. Brito-Zerón, and X. Mariette, “Systemic and organ-specific
337 immune-related manifestations of COVID-19,” *Nature Reviews Rheumatology*,
338 vol. 17, no. 6. 2021.
- 339 [4] Johns Hopkins University and Medicine, “Coronavirus Resource Center,” 2021.
340 [Online]. Available: <https://coronavirus.jhu.edu/map.html>. [Accessed: 30-Jul351
341 2021].
- 342 [5] A. G. Nerlich, C. J. Haas, A. Zink, U. Szeimies, and H. G. Hagedorn, “Molecular
343 evidence for tuberculosis in an ancient Egyptian mummy,” *Lancet*, vol. 350,
344 no.9088, p. 1404, 1997
- 345 [6] Secretaria de Vigilância em Saúde; Ministério da Saúde, *Boletim Epidemiológico*
346 *Tuberculose 2020*, 1st ed. Brasília/DF, 2020.
- 347 [7] W. Oei and H. Nishiura, “The relationship between tuberculosis and influenza
348 death during the influenza (H1N1) pandemic from 1918-19,” *Comput. Math.*
349 *Methods Med.*, vol. 2012, no. i, 2012.
- 350 [8] C.-L. Small *et al.*, “Influenza Infection Leads to Increased Susceptibility to
351 Subsequent Bacterial Superinfection by Impairing NK Cell Responses in the
352 Lung,” *J. Immunol.*, vol. 184, no. 4, pp. 2048–2056, 2010.
- 353 [9] S. Walaza *et al.*, “Influenza and tuberculosis co-infection: A systematic review,”
354 *Influenza Other Respi. Viruses*, vol. 14, no. 1, pp. 77–91, 2020.
- 355 [10] K. Zürcher, M. Zwahlen, M. Ballif, H. L. Rieder, M. Egger, and L. Fenner,
356 “Influenza pandemics and tuberculosis mortality in 1889 and 1918: Analysis of
357 historical data from Switzerland,” *PLoS One*, vol. 11, no. 10, pp. 1–11, 2016.
- 358 [11] M. R. Jabbari amiri *et al.*, “Invasive forms of *Candida* and *Aspergillus* in sputum
359 samples of pulmonary tuberculosis patients attending the tuberculosis reference
360 laboratory in Ghaemshahr, Northern Iran: An analysis of samples collected
361 during the past 10 years,” in *International Journal of Mycobacteriology*, 2016,
362 vol. 5.
- 363 [12] S. Yasri and V. Wiwanitkit, “Tuberculosis and novel Wuhan coronavirus
364 infection: Pathological interrelationship,” *Indian J. Tuberc.*, vol. 67, no. 2, p. 264,
365 2020.
- 366 [13] X. Chen *et al.*, “Serological evidence of human infection with SARS-CoV-2: a

- 367 systematic review and meta-analysis,” *Lancet Glob. Heal.*, vol. 9, no. 5, pp.
368 e598–e609, 2021.
- 369 [14] M. V. Murhekar *et al.*, “SARS-CoV-2 seroprevalence among the general
370 population and healthcare workers in India, December 2020–January 2021,” *Int.*
371 *J. Infect. Dis.*, vol. 108, pp. 145–155, 2021.
- 372 [15] P. C. Hallal *et al.*, “SARS-CoV-2 antibody prevalence in Brazil: results from two
373 successive nationwide serological household surveys,” *Lancet Glob. Heal.*, vol.
374 8, no. 11, pp. e1390–e1398, 2020.
- 375 [16] B. L. Horta *et al.*, “Prevalence of antibodies against SARS-CoV-2 according to
376 socioeconomic and ethnic status in a nationwide Brazilian survey,” *Rev. Panam.*
377 *Salud Publica/Pan Am. J. Public Heal.*, vol. 40, pp. 1–7, 2020.
- 378 [17] L. Amorim Filho *et al.*, “Seroprevalence of anti-SARS-CoV-2 among blood
379 donors in Rio de Janeiro, Brazil,” *Rev. Saude Publica*, vol. 54, pp. 1–10, 2020.
- 380 [18] J. A. Shaw *et al.*, “Higher SARS-CoV-2 seroprevalence in workers with lower
381 socioeconomic status in Cape Town, South Africa,” *PLoS One*, vol. 16, no. 2
382 February, pp. 1–12, 2021.
- 383 [19] Prefeitura da Cidade do Rio de Janeiro, “Painel Rio COVID-19 - Perfil
384 Epidemiológico 2020,” 2020. [Online]. Available:
385 [https://experience.arcgis.com/experience/38efc69787a346959c931568bd9e2cc](https://experience.arcgis.com/experience/38efc69787a346959c931568bd9e2cc4)
386 4. [Accessed: 15-May-2021].
- 387 [20] A. N. de V. S. Anvisa, “Registro ANVISA no 397 80142170039 - TR DPP®
388 COVID-19 IGM/IGG - Bio-Manguinhos.” [Online]. Available:
389 <https://consultas.anvisa.gov.br/#/saude/25351218814202000/>. [Accessed: 02-
390 Aug-2020].
- 391 [21] V. M. Corman *et al.*, “Detection of 2019 novel coronavirus (2019-nCoV) by real-
392 time RT-PCR,” *Euro Surveill.*, vol. 25, no. 3, 2020.
- 393 [22] Fiocruz. Instituto de Comunicação e Informação Científica e Tecnológica em
394 Saúde (ICICT), “MonitoraCovid-19,” 2020. [Online]. Available:
395 <https://bigdatacovid19.icict.fiocruz.br/>. [Accessed: 28-Jun-2021].
- 396 [23] M. R. Elliott and R. Valliant, “Inference for nonprobability samples,” *Stat. Sci.*,
397 vol. 32, no. 2, 2017.
- 398 [24] Y. Gao, M. Liu, Y. Chen, S. Shi, J. Geng, and J. Tian, “Association between
399 tuberculosis and COVID-19 severity and mortality: A rapid systematic review and
400 meta-analysis,” *J. Med. Virol.*, vol. 93, no. 1, pp. 194–196, 2021.
- 401 [25] N. Gupta *et al.*, “A profile of a retrospective cohort of 22 patients with COVID-19
402 and active/treated tuberculosis,” *Eur. Respir. J.*, vol. 56, no. 5, pp. 3–7, 2020.
- 403 [26] K. T. L. Sy, N. J. L. Haw, and J. Uy, “Previous and active tuberculosis increases

- 404 risk of death and prolongs recovery in patients with COVID-19,” *Infect. Dis.*
405 (*Auckl.*), vol. 52, no. 12, pp. 902–907, 2020.
- 406 [27] R. H. Du *et al.*, “Predictors of mortality for patients with COVID-19 pneumonia
407 caused by SARSCoV- 2: A prospective cohort study,” *Eur. Respir. J.*, vol. 55, no.
408 5, 2020.
- 409 [28] I. Motta *et al.*, “Tuberculosis, COVID-19 and migrants: Preliminary analysis of
410 deaths occurring in 69 patients from two cohorts,” *Pulmonology*, vol. 26, no. 4,
411 pp. 233–240, 2020.
- 412 [29] C. Stochino, S. Villa, P. Zucchi, P. Parravicini, A. Gori, and M. C. Raviglione,
413 “Clinical characteristics of COVID-19 and active tuberculosis co-infection in an
414 Italian reference hospital,” *Eur. Respir. J.*, vol. 56, no. 1, 2020.
- 415 [30] CDC, “COVID-19 Pandemic Planning Scenarios,” 2021. [Online]. Available:
416 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html>.
417 [Accessed: 15-Jun-2021].
- 418 [31] M. Alene *et al.*, “Magnitude of asymptomatic COVID-19 cases throughout the
419 course of infection: A systematic review and meta-analysis,” *PLoS ONE*, vol. 16,
420 no. 3 March. 2021.
- 421 [32] M. A. Johansson *et al.*, “SARS-CoV-2 Transmission from People without
422 COVID-19 Symptoms,” *JAMA Netw. Open*, vol. 4, no. 1, 2021.
- 423 [33] D. P. Oran and E. J. Topol, “The Proportion of SARS-CoV-2 Infections That Are
424 Asymptomatic : A Systematic Review,” *Ann. Intern. Med.*, vol. 174, no. 5, 2021.
- 425 [34] D. Buitrago-Garcia *et al.*, “Occurrence and transmission potential of
426 asymptomatic and presymptomatic SARSCoV-2 infections: A living systematic
427 review and meta-analysis,” *PLoS Medicine*, vol. 17, no. 9. 2020.
- 428 [35] M. Tadolini *et al.*, “Active tuberculosis, sequelae and COVID-19 co-infection:
429 First cohort of 49 cases,” *Eur. Respir. J.*, vol. 56, no. 1, 2020.
- 430 [36] S. Yamayoshi *et al.*, “Antibody titers against SARS-CoV-2 decline, but do not
431 disappear for several months,” *EClinicalMedicine*, vol. 32, 2021.
- 432 [37] W. H. Self *et al.*, “Decline in SARS-CoV-2 Antibodies After Mild Infection Among
433 Frontline Health Care Personnel in a Multistate Hospital Network — 12 States,
434 April–August 2020,” *MMWR. Morb. Mortal. Wkly. Rep.*, vol. 69, no. 47, pp.
435 1762–1766, 2020.
- 436 [38] Q. X. Long *et al.*, “Antibody responses to SARS-CoV-2 in patients with COVID-
437 19,” *Nat. Med.*, vol. 26, no. 6, 2020.
- 438 [39] K. Spencer, EA; Brassey, J; Mahtani, “Recall bias,” *Catalogue of Bias 2017*,
439 2017. [Online]. Available:
440 <https://www.catalogueofbiases.org/biases/recallbias%0A%0A>. [Accessed: 30-

441 Jul-2021].

442 [40] T. L. Deshields, R. C. Tait, J. D. Gfeller, and J. T. Chibnall, "Relationship
443 between social desirability and self-report in chronic pain patients," Clin. J. Pain
444 vol. 11, no. 3, 1995

445 **Table 1.** SARS-CoV-2 seroprevalence, sociodemographic indicators, previous tests and tuberculosis profile of patients under tuberculosis
 446 treatment assisted by a tertiary referral unit in Rio de Janeiro, Brazil.

Characteristic	Number of patients	Positive result	Prevalence¹	IC95%	p-value²
Overall	83	22	26.5	17.0-36.0	
Sex					0.16
Female	33 (40%)	6	18.2	7.0-35.4	
Male	50 (60%)	16	32.0	19.5-46.7	
Age (years)					>0.99
19 to 29 years old	14 (17%)	4	28.6	4.9-52.2	
30 to 59 years old	54 (65%)	14	25.9	14.2-37.6	
≥60 years old	15 (18%)	4	26.7	9.4-57.2	
Schooling					0.59
≥ 8 years	60 (72%)	15	25.0	14.0-35.9	
< 8 years	23 (28%)	7	30.4	13.1-53.5	
Ethnicity					>0.99
Branco (White)	19 (23%)	5	26.3	6.5-46.1	
Pardo (Brown)	38 (46%)	10	26.3	12.3-40.3	
Preta (Black)	26 (31%)	7	26.9	9.9-44.0	
Slum dweller					0.81
No	51 (61%)	14	27.4	15.2-39.7	

Yes	32 (39%)	8	25.0	10.0-40.0	
Monthly income					0.26
> 1 minimum wage	19 (23%)	4	21.1	2.7-39.4	
1 to 3 minimum wages	48 (58%)	13	27.1	14.5-39.6	
3 to 5 minimum wages	2 (2.4%)	0	0	-	
Did not answer	14 (17%)	5	35.7	10.6-60.8	
Previous Covid-19					>0.99
No	77 (93%)	21	27.3	17.3-37.2	
Yes	4 (4.8%)	1	25.0	0.6-80.6	
Previous RT-PCR					0.63
No	70 (84%)	20	28.6	17.9-39.1	
Yes	12 (14%)	2	16.6	2.1-48.4	
Unable to inform	1 (1.2%)	0	0	-	
Previous rapid serological test					0.88
No	60 (72%)	17	28.3	16.9-39.7	
Yes	21 (25%)	5	23.8	5.5-42.0	
Unable to inform	2 (2.4%)	0	0	-	
TB Clinic Form					0.17
Pulmonary	73 (88%)	22	30.1	20.0-42.0	
Extrapulmonary	7 (8.4%)	0	0	-	
Both	3 (3.6%)	0	0	-	
Tuberculosis type					0.30

Susceptible TB	22 (27%)	4	18.2	2.0-34.3	
Resistant TB	61 (73%)	18	29.5	18.0-40.9	
Resistance profile					0.14
Monoresistant	8 (9.6%)	3	37.5	4.0-71.0	
RMP-Resistant	16 (19%)	4	25.0	3.7-46.2	
MDR-TB	27 (33%)	5	18.5	3.9-33.2	
Polyresistant	5 (6.0%)	3	60.0	14.6-94.7	
XDR-TB	5 (6.0%)	3	60.0	14.6-94.7	
Not applicable	22 (27%)	4	18.2	7.3-38.5	
Type of case					>0.99
New case	58 (70%)	16	27.6	16.1-39.1	
Failure	9 (11%)	2	22.2	2.8-60.0	
Change of therapeutic schema	6 (7.2%)	2	33.3	4.3-77.7	
Recurrence	4 (4.8%)	1	25.0	0.6-80.6	
Re-entry after abandonment	4 (4.8%)	1	25.0	0.6-80.6	
Others	2 (2.4%)	0	0	-	

¹ Frequency (%), ² Pearson's Chi-squared test; Fisher's exact test. RMP, rifampicin; MDR-TB, tuberculosis multidrug-resistant; XDR-TB, tuberculosis extensively drug-resistant.

447 **Table 2.** Tuberculosis profile and COVID-19 test results of diagnosed patients and/or patients with SARS-CoV-2 positive serology.

	Clinical Form	TB Resistance Profile	Prior TB treatment	COVID-19 Previous Diagnosis	Serological Test Result	RT-qPCR Result (Ct)*
1	Pulmonary	Monoresistant	1	No	IgM and IgG	Non-detected
2	Pulmonary	RMP Resistant	No	1 month before the interview	Negative	Detected (20,7)
3	Pulmonary	MDR-TB	1	No	IgG	Non-detected
4	Pulmonary	Polyresistant	1	No	IgM and IgG	Non-detected
5	Pulmonary	Monoresistant	No	1 month before the interview	IgM and IgG	Non-detected
6	Pulmonary	Polyresistant	2	No	IgG	Non-detected
7	Pulmonary	MDR-TB	1	No	IgM and IgG	Detected (34,9)
8	Pulmonary	RMP Resistant	1	No	IgM and IgG	Non-detected
9	Pulmonary	Monoresistant	2	No	IgM	Non-detected
10	Pulmonary	MDR-TB	1	No	IgG	Non-detected
11	Pulmonary	RMP Resistant	No	No	IgG	Non-detected
12	Pulmonary	MDR-TB	1	No	IgG	Non-detected
13	Pulmonary	Susceptible	1	No	IgG	Non-detected
14	Pulmonary	Susceptible	No	No	IgG	Non-detected
15	Pulmonary	XDR-TB	No	No	IgG	Non-detected
16	Pulmonary	Polyresistant	1	No	IgM	Non-detected
17	Pulmonary	RMP Resistant	No	No	IgM	Non-detected
18	Pulmonary	Susceptible	No	No	Negative	Detected (24,0)
19	Pulmonary	Susceptible	No	No	IgG	Non-detected

20	Pulmonary	RMP Resistant	1	No	IgG	Non-detected
21	Pulmonary	XDR-TB	10	No	IgG	Non-detected
22**	Extrapulmonary	Susceptible	No	9 months before the interview	Negative	Non-detected
23	Pulmonary	Susceptible	1	9 months before the interview	Negative	Non-detected
24	Pulmonary	Susceptible	No	No	IgG	Non-detected
25	Pulmonary	XDR-TB	2	No	IgM and IgG	Non-detected
26	Pulmonary	MDR-TB	No	No	IgG	Non-detected

448 * Ct values for SARS-CoV-2 target “E”; **Patient who required hospitalization. RMP, rifampicin; MDR-TB, tuberculosis multidrug-resistant; XDR-TB,
449 tuberculosis extensively drug-resistant.

450 **Table 3.** Symptoms reported by patients coinfecting with TB and SARS-CoV-2 assisted
451 by a tertiary referral unit in Rio de Janeiro, Brazil.

Symptoms	Coinfected patients (%)¹
Fever	6 (75%)
Headache	6 (75%)
Myalgia	6 (75%)
Coryza	3 (38%)
Dry cough	3 (38%)
Smell Loss	3 (38%)
Diarrhea	3 (38%)
Dyspnea	2 (25%)
Abdominal pain	2 (25%)
Chest pain	2 (25%)
Productive cough	2 (25%)
Emesis	2 (25%)
Taste loss	2 (25%)
Sore throat	1 (13%)
Symptomatic patients	8 (31%)
Asymptomatic patients	18 (69%)

¹COVID-19 diagnosed and/or SARS-CoV-2 antibodies positive patients.

452 **Table 4.** Risk factors for COVID-19 reported by patients under TB treatment assisted
453 by a tertiary referral unit in Rio de Janeiro, Brazil.

COVID-19 Risk factors	Total	Coinfected patients¹
Over 60 years old	14 (32%)	4 (15%)
Pregnant	1 (2.3%)	0 (0%)
Heart disease	1 (2.3%)	0 (0%)
Hypertension	3 (6.8%)	1 (4%)
Diabetes	12 (27%)	3 (12%)
Kidney disease	3 (6.8%)	1 (4%)
Neurological disease	2 (4.5%)	1 (4%)
Cancer	1 (2.3%)	0 (0%)
Smoking	6 (14%)	1 (4%)
HIV	6 (14%)	2 (8%)
Total patients with risk factors	44 (53%)	11 (42%)
Total patients without risk factors	35 (42%)	12 (46%)
Did not know or want to inform	4 (5%)	3 (12%)

454 ¹COVID-19 diagnosed and/or SARS-CoV-2 antibodies positive patients.